Investors looking for stocks that can produce dramatic gains over the next 12 months want to turn their attention to the biotechnology industry. Wall Street analysts tasked with following a synthetic biology company called Ginkgo Bioworks (NYSE: DNA) think it can more than double your money.

Investment bankers also have high hopes for Agenus (NASDAQ: AGEN). The latest price targets on the cancer drug developer suggest it can shoot more than 700% higher.

Shares of Ginkgo Bioworks are down about 54% from a peak they hit last summer. Investment bank analysts at TD Cowen think it can rebound. In March, the bank lowered its price target on the stock to $3 per share. The lowered target still implies a gain of over 150% from the stock's recent price.

Continue reading

Source Fool.com